Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Multiple Endocrine Neoplasia Type 2a 1Lethal Congenital Contracture Syndrome 2 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 206pembrolizumab 169Pemetrexed 145Cisplatin 127Paclitaxel 78durvalumab 76osimertinib 71Nivolumab 69Docetaxel 66Specimen Handling 64atezolizumab 62Magnetic Resonance Spectroscopy 54Etoposide 47Gemcitabine 46Radiotherapy 45Radiosurgery 40130-nm albumin-bound paclitaxel 36Drug Therapy 33Bevacizumab 29Ipilimumab 28Cetuximab 28cemiplimab 25Taxes 24tislelizumab 21Platinum 21Immunoglobulin G 21Radiation 20Biopsy 20amivantamab 19Disulfides 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Antibodies, Bispecific × Thoracic × 90 days × Clear all
NCT05142189 2026-04-14

LuCa-MERIT-1

BioNTech SE

Phase 1 Recruiting
320 enrolled
EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

Data powered by HemOnc (CC BY 4.0) Colophon âš¡